A Phase 1 interventional study of MK-8527 in Human Immunodeficiency Virus, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-03-26.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-dose clinical study to evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-8527 in antiretroviral therapy (ART)-naïve participants living with human immunodeficiency virus type 1 (HIV-1) infection. The primary hypothesis is that, at a dose that is safe and generally well tolerated, MK-8527 will have antiretroviral activity as measured by a reduction from baseline in plasma HIV-1 ribonucleic acid (RNA) of ≥1.0 log10 copies/mL. A total of 4 arms was initially planned but Arm D was never initiated as the primary objectives were achieved following completion of Arms A to C.
3,037 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 20 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single oral dose of MK-8527 1.0 mg.
Drug: MK-8527
Participants receive a single oral dose of MK-8527 0.5 mg.
Drug: MK-8527
Participants receive a single oral dose of MK-8527 0.25 mg.
Drug: MK-8527
MK-8527 capsule taken by mouth.
Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA)
The mean change from baseline in HIV-1 RNA counts at 168 hours after a single doses of MK-8527 is reported.
Time frame: Baseline and 168 hours postdose on Day 1
Number of Participants Experiencing ≥1 Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 28 days
Number of Participants Discontinuing From Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to 28 days
Area Under the Concentration-Time Curve From Predose to 168 Hours Postdose (AUC0-168) of MK-8527 Triphosphate (MK-8527-TP) in Peripheral Blood Mononuclear Cells (PBMCs)
The AUC0-168 of MK-8527-TP in PBMCs is reported.
Time frame: Predose and 4, 12, 24, 96, 120, 144, and 168 hours postdose
Area Under the Concentration-Time Curve From Predose to Infinity (AUC0-inf) of MK-8527-TP in PBMCs
The MK-8527-TP AUC0-inf in PBMCs is reported.
Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Area Under the Concentration-Time Curve From Predose to Last Measurable Concentration (AUC0-last) of MK-8527-TP in PBMCs
The MK-8527-TP AUC0-last in PBMCs is reported.
Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Maximum Concentration (Cmax) of MK-8527-TP in PBMCs
The MK-8527-TP Cmax in PBMCs is reported.
Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Concentration at 168 Hours Postdose (C168) of MK-8527-TP in PBMCs
The C168 of MK-8527-TP in PBMCs is reported.
Time frame: 168 hours postdose
Time to Maximum Concentration (Tmax) of MK-8527-TP in PBMCs
The MK-8527-TP Tmax in PBMCs is reported.
Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
Apparent Terminal Half-life (t½) of MK-8527-TP in PBMCs
The apparent t½ of MK-8527-TP in PBMCs is reported.
Time frame: Predose and 4, 12, 24, 96, 120, 144, 168, 192, 240, 336, 504, and 672 hours postdose
AUC0-inf of MK-8527 in Plasma
The AUC0-inf of MK-8527 in plasma is reported.
Time frame: Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
AUC0-last of MK-8527 in Plasma
The AUC0-last of MK-8527 in plasma is reported.
Time frame: Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Clast of MK-8527 in Plasma
The Clast of MK-8527 in plasma is reported.
Time frame: Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Cmax of MK-8527 in Plasma
The Cmax of MK-8527 in plasma is reported.
Time frame: Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Tmax of MK-8527 in Plasma
The Tmax of MK-8527 in plasma is reported.
Time frame: Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Apparent t½ of MK-8527 in Plasma
The apparent t½ of MK-8527 in plasma is reported.
Time frame: Predose and 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Correlation Between Intracellular C168 of MK-8527-TP in PBMCs and Change From Baseline in Plasma HIV-1 RNA
The correlation between between the C168 of MK-8527-TP in PBMCs and the change from baseline in plasma HIV-1 RNA levels 168 hours after dosing was calculated based on all pooled participants. All participants who complied with the protocol sufficiently to ensure that generated data will belikely to exhibit the effects of treatment, according to the underlying scientific model, are included. Participants with data below the LLOQ are excluded.
Time frame: Predose and 168 hours postdose
| Milestone | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Started | 8 | 6 | 6 |
| Completed | 8 | 6 | 6 |
| Not completed | 0 | 0 | 0 |
The mean change from baseline in HIV-1 RNA counts at 168 hours after a single doses of MK-8527 is reported.
| HIV-1 RNA copies/mL | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) | -1.38 (-1.61 to -1.15) | -1.40 (-1.66 to -1.13) | -0.80 (-1.06 to -0.53) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Number of Participants Experiencing ≥1 Adverse Event (AE) | 5 | 5 | 2 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Number of Participants Discontinuing From Study Due to an AE | 0 | 0 | 0 |
The AUC0-168 of MK-8527-TP in PBMCs is reported.
| h*pmol/10^6 cells | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Area Under the Concentration-Time Curve From Predose to 168 Hours Postdose (AUC0-168) of MK-8527 Triphosphate (MK-8527-TP) in Peripheral Blood Mononuclear Cells (PBMCs) | 29.2 (24.1 to 35.3) | 12.6 (10.1 to 15.7) | 5.53 (4.44 to 6.89) |
The MK-8527-TP AUC0-inf in PBMCs is reported.
| h*pmol/10^6 cells | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Area Under the Concentration-Time Curve From Predose to Infinity (AUC0-inf) of MK-8527-TP in PBMCs | 47.7 (37.8 to 60.3) | 24.5 (18.7 to 32.1) | 8.87 (6.60 to 11.9) |
The MK-8527-TP AUC0-last in PBMCs is reported.
| h*pmol/10^6 cells | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Area Under the Concentration-Time Curve From Predose to Last Measurable Concentration (AUC0-last) of MK-8527-TP in PBMCs | 40.9 (32.5 to 51.4) | 17.1 (13.1 to 22.2) | 5.88 (4.51 to 7.66) |
The MK-8527-TP Cmax in PBMCs is reported.
| pmol/10^6 cells | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Maximum Concentration (Cmax) of MK-8527-TP in PBMCs | 0.270 (0.232 to 0.314) | 0.134 (0.113 to 0.160) | 0.0535 (0.0449 to 0.0637) |
The C168 of MK-8527-TP in PBMCs is reported.
| pmol/10^6 cells | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Concentration at 168 Hours Postdose (C168) of MK-8527-TP in PBMCs | 0.111 (0.0808 to 0.152) | 0.0484 (0.0344 to 0.0681) | 0.0224 (0.0154 to 0.0325) |
The MK-8527-TP Tmax in PBMCs is reported.
| hours | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Time to Maximum Concentration (Tmax) of MK-8527-TP in PBMCs | 24.00 (12.00 to 24.05) | 24.03 (12.07 to 24.68) | 23.91 (12.00 to 24.12) |
The apparent t½ of MK-8527-TP in PBMCs is reported.
| Hours | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Apparent Terminal Half-life (t½) of MK-8527-TP in PBMCs | 128.24 ± 49.00 | 172.09 ± 90.23 | 80.15 ± 52.35 |
The AUC0-inf of MK-8527 in plasma is reported.
| h*umol/L | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| AUC0-inf of MK-8527 in Plasma | 0.0512 (0.0360 to 0.0728) | NA (NA to NA) | NA (NA to NA) |
The AUC0-last of MK-8527 in plasma is reported.
| h*umol/L | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| AUC0-last of MK-8527 in Plasma | 0.0304 (0.0221 to 0.0419) | NA (NA to NA) | NA (NA to NA) |
The Clast of MK-8527 in plasma is reported.
| umol/L | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Clast of MK-8527 in Plasma | 0.00388 (0.00346 to 0.00435) | 0.00433 (0.00380 to 0.00495) | 0.00417 (0.00361 to 0.00482) |
The Cmax of MK-8527 in plasma is reported.
| umol/L | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Cmax of MK-8527 in Plasma | 0.0224 (0.0172 to 0.0292) | 0.00935 (0.00688 to 0.0127) | 0.00469 (0.00335 to 0.00656) |
The Tmax of MK-8527 in plasma is reported.
| Hours | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Tmax of MK-8527 in Plasma | 0.50 (0.50 to 1.00) | 0.50 (0.50 to 3.00) | 0.50 (0.23 to 1.00) |
The apparent t½ of MK-8527 in plasma is reported.
| Hours | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| Apparent t½ of MK-8527 in Plasma | 3.25 ± 54.52 | NA ± NA | NA ± NA |
The correlation between between the C168 of MK-8527-TP in PBMCs and the change from baseline in plasma HIV-1 RNA levels 168 hours after dosing was calculated based on all pooled participants. All participants who complied with the protocol sufficiently to ensure that generated data will belikely to exhibit the effects of treatment, according to the underlying scientific model, are included. Participants with data below the LLOQ are excluded.
| Pearson r coefficient | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg | Panels A to C: MK-8527 Pooled |
|---|---|---|---|---|
| Correlation Between Intracellular C168 of MK-8527-TP in PBMCs and Change From Baseline in Plasma HIV-1 RNA | NA | NA | NA | -0.342 |
Collected over Up to 28 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panel A: MK-8527 1.0 mg | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Panel B: MK-8527 0.5 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Panel D: MK-8527 0.25 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel D: MK-8527 0.25 mg |
|---|---|---|---|
| HeadacheNervous system disorders | 2/8 | 1/6 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 1/6 | 0/6 |
| DyspepsiaGastrointestinal disorders | 0/8 | 0/6 | 1/6 |
| NauseaGastrointestinal disorders | 0/8 | 1/6 | 0/6 |
| Vessel puncture site bruiseGeneral disorders | 0/8 | 1/6 | 0/6 |
| ImpetigoInfections and infestations | 1/8 | 1/6 | 0/6 |
| Tinea facieiInfections and infestations | 1/8 | 1/6 | 0/6 |
| Urinary tract infectionInfections and infestations | 1/8 | 1/6 | 0/6 |
| CarbuncleInfections and infestations | 0/8 | 1/6 | 0/6 |
| FuruncleInfections and infestations | 0/8 | 1/6 | 0/6 |
There were no participants in Panel D.
| Age, Continuous(years) | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg | Total |
|---|---|---|---|---|
| Mean | 30.0 ± 8.6 | 23.8 ± 3.5 | 37.8 ± 12.6 | 30.5 ± 10.2 |
| Sex: Female, Male(Participants) | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg | Total |
|---|---|---|---|---|
| Female | 5 | 6 | 2 | 13 |
| Male | 3 | 0 | 4 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 8 | 6 | 6 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 6 | 2 | 16 |
| White | 0 | 0 | 4 | 4 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2022 to primary completion in Jan 2024, 14 months.
Results were first posted in Mar 2025, 1 year 1 month after primary completion.
Of 76 industry-sponsored phase 1 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 14 months is above that.
Counting every sponsor, half of 139 studies reached it within 14 months; a quarter within 4 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alimatravir
Acquired Immunodeficiency Syndrome →